Patents by Inventor Bernard Luke Flynn

Bernard Luke Flynn has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • INHIBITOR COMPOUNDS
    Publication number: 20220274970
    Abstract: The disclosure relates to heterocyclic compounds and methods for their preparation. The disclosure provides compounds that may have beneficial therapeutic activity in the treatment of a disease or condition mediated by excessive or otherwise undesirable Des1 and/or fibrotic activity.
    Type: Application
    Filed: July 24, 2020
    Publication date: September 1, 2022
    Applicant: Cincera Therapeutics Pty Ltd
    Inventors: Bernard Luke FLYNN, Giang LE, Shuxin YANG
  • Anxiolytic compounds
    Patent number: 10954231
    Abstract: The present invention relates to chemical compounds of general formula (I): which may possess useful therapeutic activity in a range of central nervous system disorders, and in particular, anxiety disorders.
    Type: Grant
    Filed: December 15, 2017
    Date of Patent: March 23, 2021
    Assignee: Bionomics Limited
    Inventors: Jonathan Bayldon Baell, Brad Sleebs, Bernard Luke Flynn, Ian Phillip Street, Nurul Quazi, Chinh Thien Bui
  • Salts, co-crystals, and polymorphs of an anxiolytic compound
    Patent number: 10266529
    Abstract: The present invention provides crystalline Forms FUM-P3, FUM-P4, MLA-P3 and MLA-P4 of compound formula 1 and related methods of treating and/or preventing a disease, such as a central nervous system disease (e.g., an anxiety disorder), using a crystalline Form FUM-P3, FUM-P4, MLA-P3 and MLA-P4 of compound formula 1 and/or pharmaceutical compositions thereof.
    Type: Grant
    Filed: August 25, 2017
    Date of Patent: April 23, 2019
    Assignees: Bionomics Limited, Ironwood Pharmaceuticals, Inc.
    Inventors: Bernard Luke Flynn, Dharam Paul, Andrew John Harvey, Vasu V. Sethuraman, Raymond E. Forslund, Song Xue, Rob Livingston, Ahmad Hashash
  • Anxiolytic compounds
    Patent number: 10233181
    Abstract: The present invention relates to chemical compounds of general formula (I) which may possess useful therapeutic activity in a range of central nervous system disorders, and in particular, anxiety disorders.
    Type: Grant
    Filed: December 15, 2017
    Date of Patent: March 19, 2019
    Assignee: Bionomics Limited
    Inventors: Jonathan Bayldon Baell, Brad Sleebs, Bernard Luke Flynn, Ian Phillip Street, Nurul Quazi, Chinh Thien Bui
  • Substituted benzofurans, benzothiophenes, benzoselenophenes and indoles and their use as tubulin polymerisation inhibitors
    Patent number: 10213409
    Abstract: The present invention relates generally to substituted benzofurans, benzothiophenes, and indoles and their use as tubulin polymerization inhibitors.
    Type: Grant
    Filed: April 28, 2016
    Date of Patent: February 26, 2019
    Assignee: BIONOMICS LIMITED
    Inventors: Jason Hugh Chaplin, Gurmit Sing Gill, Damian Wojciech Grobelny, Bernard Luke Flynn, Gabriel Kremmidiotis
  • Anxiolytic compounds
    Patent number: 9975892
    Abstract: The present invention relates to chemical compounds of general formula (I) which may possess useful therapeutic activity in a range of central nervous system disorders, and in particular, anxiety disorders.
    Type: Grant
    Filed: January 4, 2017
    Date of Patent: May 22, 2018
    Assignee: Bionomics Limited
    Inventors: Jonathan Bayldon Baell, Brad Sleebs, Bernard Luke Flynn, Ian Phillip Street, Nurul Quazi, Chinh Thien Bui
  • NOVEL ANXIOLYTIC COMPOUNDS
    Publication number: 20180105524
    Abstract: The present invention relates to chemical compounds of general formula (I) which may possess useful therapeutic activity in a range of central nervous system disorders, and in particular, anxiety disorders.
    Type: Application
    Filed: December 15, 2017
    Publication date: April 19, 2018
    Applicant: Bionomics Limited
    Inventors: Jonathan Bayldon Baell, Brad Sleebs, Bernard Luke Flynn, Ian Phillip Street, Nurul Quazi, Chinh Thien Bui
  • NOVEL ANXIOLYTIC COMPOUNDS
    Publication number: 20180105523
    Abstract: The present invention relates to chemical compounds of general formula (I): which may possess useful therapeutic activity in a range of central nervous system disorders, and in particular, anxiety disorders.
    Type: Application
    Filed: December 15, 2017
    Publication date: April 19, 2018
    Applicant: Bionomics Limited
    Inventors: Jonathan Bayldon Baell, Brad Sleebs, Bernard Luke Flynn, Ian Phillip Street, Nurul Quazi, Chinh Thien Bui
  • SALTS, CO-CRYSTALS, AND POLYMORPHS OF AN ANXIOLYTIC COMPOUND
    Publication number: 20170362230
    Abstract: The present invention provides crystalline Forms FUM-P3, FUM-P4, MLA-P3 and MLA-P4 of compound formula 1 and related methods of treating and/or preventing a disease, such as a central nervous system disease (e.g., an anxiety disorder), using a crystalline Form FUM-P3, FUM-P4, MLA-P3 and MLA-P4 of compound formula 1 and/or pharmaceutical compositions thereof.
    Type: Application
    Filed: August 25, 2017
    Publication date: December 21, 2017
    Inventors: Bernard Luke FLYNN, Dharam PAUL, Andrew John HARVEY, Vasu V. SETHURAMAN, Raymond E. FORSLUND, Song XUE, Rob LIVINGSTON, Ahmad HASHASH
  • Enzyme interacting agents
    Patent number: 9828351
    Abstract: The present disclosure relates generally, but not exclusively, to compounds and their use as enzyme interacting agents, in particular, agents which interact with one or more enzymes in the sphingolipid biosynthesis pathway. The disclosure further relates to the use of such compounds as research tools, use in therapy, to compositions and agents comprising said compounds, and to methods of treatment using said compounds.
    Type: Grant
    Filed: June 26, 2015
    Date of Patent: November 28, 2017
    Assignees: MONASH UNIVERSITY, UNIVERSITY OF SOUTH AUSTRALIA, CENTRAL ADELAIDE LOCAL HEALTH NETWORK INCORPORATED
    Inventors: Bernard Luke Flynn, Luigi Aurelio, Carmen Vittoria Scullino, Bing Hui Wang, Stuart Maxwell Pitson, Melissa Rose Pitman
  • CRYSTALLINE FORM OF AN ANXIOLYTIC COMPOUND
    Publication number: 20170305905
    Abstract: The present invention provides a crystalline Form B of compound 1, and pharmaceutically compositions thereof. The present invention also provides methods of treating a disease (e.g., a disease of the central nervous system) using the pharmaceutical compositions.
    Type: Application
    Filed: June 29, 2017
    Publication date: October 26, 2017
    Inventors: Bernard Luke Flynn, Dharam Paul, Andrew John Harvey
  • Crystalline form of an anxiolytic compound
    Patent number: 9758516
    Abstract: A crystalline Form B of compound 1 can be used in pharmaceutically compositions. The pharmaceutical compositions can be used in methods of treating a disease (e.g., a disease of the central nervous system).
    Type: Grant
    Filed: May 14, 2013
    Date of Patent: September 12, 2017
    Assignee: BIONOMICS LIMITED
    Inventors: Bernard Luke Flynn, Dharam Paul, Andrew John Harvey
  • Salts, co-crystals, and polymorphs of an anxiolytic compound
    Patent number: 9745296
    Abstract: The present invention provides amorphous arid crystalline forms of 1-ethyl-6-(indan-2-ylamino)-3-(morpholine-4-carbonyl)-1,8-naphthyridin-4-one (compound 1), and salts, co-crystals, and pharmaceutical compositions thereof. The invention also provides methods of treating and/or preventing a disease, such as a central nervous system disease (e.g., an anxiety disorder), using the amorphous and crystalline forms, and salts, co-crystals, and pharmaceutical compositions thereof.
    Type: Grant
    Filed: March 14, 2014
    Date of Patent: August 29, 2017
    Assignees: BIONOMICS LIMITED, IRONWOOD PHARMACEUTICALS, INC.
    Inventors: Bernard Luke Flynn, Dharam Paul, Andrew John Harvey, Vasu V. Sethuraman, Raymond E. Forslund, Song Xue, Rob Livingston, Ahmad Hashash
  • ENZYME INTERACTING AGENTS
    Publication number: 20170190698
    Abstract: The present disclosure relates generally, but not exclusively, to compounds and their use as enzyme interacting agents, in particular, agents which interact with one or more enzymes in the sphingolipid biosynthesis pathway. The disclosure further relates to the use of such compounds as research tools, use in therapy, to compositions and agents comprising said compounds, and to methods of treatment using said compounds.
    Type: Application
    Filed: June 26, 2015
    Publication date: July 6, 2017
    Inventors: Bernard Luke Flynn, Luigi Aurelio, Carmen Vittoria Scullino, Bing Hui Wang, Stuart Maxwell Pitson, Melissa Rose Pitman
  • NOVEL ANXIOLYTIC COMPOUNDS
    Publication number: 20170183347
    Abstract: The present invention relates to chemical compounds of general formula (I) which may possess useful therapeutic activity in a range of central nervous system disorders, and in particular, anxiety disorders.
    Type: Application
    Filed: January 4, 2017
    Publication date: June 29, 2017
    Applicant: Bionomics Limited
    Inventors: Jonathan Bayldon Baell, Brad Sleebs, Bernard Luke Flynn, Ian Phillip Street, Nurul Quazi, Chinh Thien Bui
  • Anxiolytic compounds
    Patent number: 9573945
    Abstract: The present invention relates to chemical compounds of general formula (I) which may possess useful therapeutic activity in a range of central nervous system disorders, and in particular, anxiety disorders.
    Type: Grant
    Filed: November 5, 2014
    Date of Patent: February 21, 2017
    Assignee: Bionomics Limited
    Inventors: Jonathan Bayldon Baell, Brad Sleebs, Bernard Luke Flynn, Ian Phillip Street, Nurul Quazi, Chinh Thien Bui
  • SUBSTITUTED BENZOFURANS, BENZOTHIOPHENES, BENZOSELENOPHENES AND INDOLES AND THEIR USE AS TUBULIN POLYMERISATION INHIBITORS
    Publication number: 20170020840
    Abstract: The present invention relates generally to substituted benzofurans, benzothiophenes, and indoles and their use as tubulin polymerisation inhibitors.
    Type: Application
    Filed: April 28, 2016
    Publication date: January 26, 2017
    Inventors: JASON HUGH CHAPLIN, GURMIT SING GILL, DAMIAN WOJCIECH GROBELNY, BERNARD LUKE FLYNN, GABRIEL KREMMIDIOTIS
  • SALTS, CO-CRYSTALS, AND POLYMORPHS OF AN ANXIOLYTIC COMPOUND
    Publication number: 20160185770
    Abstract: The present invention provides amorphous arid crystalline forms of 1-ethyl-6-(indan-2-ylamino)-3-(morpholine-4-carbonyl)-1,8-naphthyridin-4-one (compound 1), and salts, co-crystals, and pharmaceutical compositions thereof. The invention also provides methods of treating and/or preventing a disease, such as a central nervous system disease (e.g., an anxiety disorder), using the amorphous and crystalline forms, and salts, co-crystals, and pharmaceutical compositions thereof.
    Type: Application
    Filed: March 14, 2014
    Publication date: June 30, 2016
    Inventors: Bernard Luke FLYNN, Dharam PAUL, Andrew John HARVEY, Vasu V. SETHURAMAN, Raymond E. FORSLUND, Song XUE, Rob LIVINGSTON, Ahmad HASHASH
  • Substituted benzofurans, benzothiophenes, benzoselenophenes and indoles and their use as tubulin polymerisation inhibitors
    Patent number: 9346842
    Abstract: The present invention relates generally to substituted benzofurans, benzothiophenes, and indoles and their use as tubulin polymerization inhibitors.
    Type: Grant
    Filed: February 19, 2014
    Date of Patent: May 24, 2016
    Assignee: Bionomics Limited
    Inventors: Jason Hugh Chaplin, Gurmit Singh Gill, Damian Wojciech Grobelny, Bernard Luke Flynn, Gabriel Kremmidiotis
  • A CRYSTALLINE FORM OF AN ANXIOLYTIC COMPOUND
    Publication number: 20160039810
    Abstract: A crystalline Form B of compound 1 can be used in pharmaceutically compositions. The pharmaceutical compositions can be used in methods of treating a disease (e.g., a disease of the central nervous system).
    Type: Application
    Filed: May 14, 2013
    Publication date: February 11, 2016
    Applicant: Bionomics Limited
    Inventors: Bernard Luke FLYNN, Dharam PAUL, Andrew John HARVEY